Imiquimod-loaded nanoarchaeosomes as a promising immunotherapy against Trypanosoma cruzi infection.
Colloids Surf B Biointerfaces
; 189: 110850, 2020 May.
Article
in En
| MEDLINE
| ID: mdl-32058257
ABSTRACT
The purpose of this study was to evaluate the efficacy of imiquimod-containing nanovesicles prepared with lipids extracted from the hyperhalophile archaebacterium Halorubrum tebenquichense (nanoARC-IMQ) to induce protection against Trypanosoma cruzi infection. The therapeutic efficacy of archaeolipid nanovesicles was assessed in an experimental murine model of acute infection with T. cruzi. The administration of nanoARQ-IMQ prevented mortality as compared to infected untreated animals, reduced parasitemia levels and diminished myocardial and musculoskeletal lesions in mice infected with a lethal strain of T. cruzi. Our findings suggest that the immunotherapy with nanoARC-IMQ has potential to limit the progression of Chagas disease.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Adjuvants, Immunologic
/
Chagas Disease
/
Nanoparticles
/
Imiquimod
/
Immunotherapy
Type of study:
Prognostic_studies
Limits:
Animals
Language:
En
Journal:
Colloids Surf B Biointerfaces
Journal subject:
QUIMICA
Year:
2020
Type:
Article
Affiliation country:
Argentina